| scholarly article | Q13442814 |
| P50 | author | Lourdes Farré | Q55271311 |
| Ramón Mangues | Q55603191 | ||
| Isolda Casanova | Q73299593 | ||
| P2093 | author name string | Mazo A | |
| Guerrero S | |||
| Capellà G | |||
| P433 | issue | 23 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | apoptotic process | Q14599311 |
| overexpression | Q61643320 | ||
| P304 | page(s) | 6750-6756 | |
| P577 | publication date | 2000-12-01 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression | |
| P478 | volume | 60 |
| Q92286756 | A Review on Dietary Intervention in Obesity Associated Colon Cancer |
| Q35402251 | A specific KRAS codon 13 mutation is an independent predictor for colorectal cancer metachronous distant metastases |
| Q33811768 | Aberrant DNA methylation in hereditary nonpolyposis colorectal cancer without mismatch repair deficiency |
| Q64238513 | An occult urothelial carcinoma with wide multiorgan metastases and its genetic alteration profiling: Case report and literature review |
| Q41525845 | Analysis of K-Ras Interactions by Biotin Ligase Tagging. |
| Q34259118 | Antagonistic effect of flavonoids on NSC-741909-mediated antitumor activity via scavenging of reactive oxygen species |
| Q26828992 | Are KRAS/BRAF Mutations Potent Prognostic and/or Predictive Biomarkers in Colorectal Cancers? |
| Q36416491 | Association Between Specific Mutations in KRAS Codon 12 and Colorectal Liver Metastasis. |
| Q34607305 | Association between specific KRAS mutations and the clinicopathological characteristics of colorectal tumors |
| Q34517338 | BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients |
| Q34394189 | CRR9/CLPTM1L regulates cell survival signaling and is required for Ras transformation and lung tumorigenesis |
| Q40313679 | Cholecystokinin 1 receptor modulates the MEKK1-induced c-Jun trans-activation: structural requirements of the receptor |
| Q41044367 | Clinical parameters to guide decision-making in elderly metastatic colorectal CANCER patients treated with intensive cytotoxic and anti-angiogenic therapy. |
| Q35579056 | Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages |
| Q35109213 | Comparative analysis of KRAS codon 12, 13, 18, 61, and 117 mutations using human MCF10A isogenic cell lines |
| Q92709364 | Comprehensive characterization of RAS mutations in colon and rectal cancers in old and young patients |
| Q34598203 | Computational analysis of KRAS mutations: implications for different effects on the KRAS p.G12D and p.G13D mutations |
| Q26740067 | Current targeted therapies in the treatment of advanced colorectal cancer: a review |
| Q38238599 | Decoding RAS isoform and codon-specific signalling. |
| Q46148260 | Differential KrasV12 protein levels control a switch regulating lung cancer cell morphology and motility |
| Q40346822 | Differential in vivo tumorigenicity of diverse KRAS mutations in vertebrate pancreas: A comprehensive survey. |
| Q37401956 | Differential prognosis of metastatic colorectal cancer patients post-progression to first-line triplet chemotherapy plus bevacizumab, FIr-B/FOx, according to second-line treatment and KRAS genotype |
| Q35166709 | Differential reprogramming of isogenic colorectal cancer cells by distinct activating KRAS mutations |
| Q33635144 | Diversity of Precursor Lesions For Pancreatic Cancer: The Genetics and Biology of Intraductal Papillary Mucinous Neoplasm |
| Q34149887 | EGFR-targeted TRAIL and a Smac mimetic synergize to overcome apoptosis resistance in KRAS mutant colorectal cancer cells |
| Q92089031 | Emergence of KRAS p.G13D mutation and acquired resistance to cetuximab in colorectal cancer with vulvar metastasis: A case report |
| Q36557197 | Enhanced cell migration and apoptosis resistance may underlie the association between high SERPINE1 expression and poor outcome in head and neck carcinoma patients. |
| Q34478077 | Frequent Epigenetic Silencing of the Folate-Metabolising Gene Cystathionine-Beta-Synthase in Gastrointestinal Cancer |
| Q64982130 | Genetic characterisation of molecular targets in carcinoma of unknown primary. |
| Q90647892 | Impact of RAS mutation subtype on clinical outcome-a cross-entity comparison of patients with advanced non-small cell lung cancer and colorectal cancer |
| Q43811983 | Impact of second-line and later cetuximab-containing therapy and KRAS genotypes in patients with metastatic colorectal cancer: a multicenter study in Japan |
| Q36648105 | Incidence, mechanism and prognostic value of activated AKT in pancreas cancer |
| Q54301071 | Involvement of K-RAS mutations and amino acid substitutions in the survival of metastatic colorectal cancer patients. |
| Q36797103 | Involvement of KRAS G12A mutation in the IL-2-independent growth of a human T-LGL leukemia cell line, PLT-2 |
| Q92477586 | Isoform-Specific Destabilization of the Active Site Reveals a Molecular Mechanism of Intrinsic Activation of KRas G13D |
| Q49668169 | KRAS Alleles: The Devil Is in the Detail |
| Q48097655 | KRAS Exon 2 Mutations as Prognostic Indicators in Advanced Colorectal Cancer in Clinical Practice: A Mono-Institutional Study |
| Q34039936 | KRAS G13D Mutation and Sensitivity to Cetuximab or Panitumumab in a Colorectal Cancer Cell Line Model |
| Q92734257 | KRAS and BRAF Mutations as Prognostic and Predictive Biomarkers for Standard Chemotherapy Response in Metastatic Colorectal Cancer: A Single Institutional Study |
| Q35045790 | KRAS and BRAF gene mutations and DNA mismatch repair status in Chinese colorectal carcinoma patients |
| Q53304753 | KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy |
| Q90216637 | KRAS and BRAF mutations induce anoikis resistance and characteristic 3D phenotypes in Caco‑2 cells |
| Q34157801 | KRAS and DAXX/ATRX gene mutations are correlated with the clinicopathological features, advanced diseases, and poor prognosis in Chinese patients with pancreatic neuroendocrine tumors |
| Q33693309 | KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance). |
| Q37709323 | KRAS exon 2 codon 13 mutation is associated with a better prognosis than codon 12 mutation following lung metastasectomy in colorectal cancer |
| Q36100844 | KRAS mutant colorectal tumors: past and present |
| Q39270840 | KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines |
| Q24598640 | Markers of resistance to anti-EGFR therapy in colorectal cancer |
| Q43182172 | Meta-analysis of the mutational status of circulation tumor cells and paired primary tumor tissues from colorectal cancer patients |
| Q42354892 | MicroRNAs: a new tool in the complex biology of KRAS mutated non-small cell lung cancer? |
| Q37139174 | Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention |
| Q49679318 | Mutations in KRAS codon 12 predict poor survival in Chinese patients with metastatic colorectal cancer |
| Q41614877 | Mutations in Specific Codons of the KRAS Oncogene are Associated with Variable Resistance to Neoadjuvant Chemoradiation Therapy in Patients with Rectal Adenocarcinoma |
| Q36712670 | NMR-based functional profiling of RASopathies and oncogenic RAS mutations. |
| Q38114835 | New targets in non-small cell lung cancer |
| Q92617679 | Not all mutations of KRAS predict poor prognosis in patients with colorectal cancer |
| Q35882193 | Oncogenic KRAS impairs EGFR antibodies' efficiency by C/EBPβ-dependent suppression of EGFR expression |
| Q37123400 | Overexpressed vs mutated Kras in murine fibroblasts: a molecular phenotyping study. |
| Q26822817 | Personalized treatment for advanced colorectal cancer: KRAS and beyond |
| Q91756078 | Phenotypic characterization of the novel, non-hotspot oncogenic KRAS mutants E31D and E63K |
| Q39716970 | Phosphoproteomic Analyses of NRAS(G12) and NRAS(Q61) Mutant Melanocytes Reveal Increased CK2α Kinase Levels in NRAS(Q61) Mutant Cells. |
| Q37697540 | Predictive and prognostic biomarkers with therapeutic targets in advanced colorectal cancer. |
| Q38582586 | Prognostic and Predictive Value of RAS Gene Mutations in Colorectal Cancer: Moving Beyond KRAS Exon 2. |
| Q35775729 | Prognostic impact of KRAS mutation subtypes in 677 patients with metastatic lung adenocarcinomas |
| Q33778129 | Prognostic relevance of KRAS genotype in metastatic colorectal cancer patients unfit for FIr-B/FOx intensive regimen |
| Q38600228 | Prognostic value of KRAS codon 13 gene mutation for overall survival in colorectal cancer: Direct and indirect comparison meta-analysis. |
| Q34470974 | Prognostic value of KRAS genotype in metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) according to extension of metastatic disease |
| Q35125613 | Pyrosequencing-based methods reveal marked inter-individual differences in oncogene mutation burden in human colorectal tumours |
| Q35683647 | RAS Mutations and Oncogenesis: Not all RAS Mutations are Created Equally |
| Q57033842 | RAS variant signalling |
| Q40961495 | Rapid and sensitive detection of UGT1A1 polymorphisms associated with irinotecan toxicity by a novel DNA microarray. |
| Q42160986 | Role of KRAS mutation as predictor of pathologic response after neoadjuvant chemoradiation therapy for rectal cancer |
| Q37243407 | Site-dependent differences in clinical, pathohistological, and molecular parameters in metastatic colon cancer |
| Q39139086 | Specific mutations in KRAS codon 12 are associated with worse overall survival in patients with advanced and recurrent colorectal cancer |
| Q36761405 | Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers |
| Q37339461 | Suppression of MicroRNA 200 Family Expression by Oncogenic KRAS Activation Promotes Cell Survival and Epithelial-Mesenchymal Transition in KRAS-Driven Cancer |
| Q34626362 | The impact of KRAS mutations on VEGF-A production and tumour vascular network |
| Q35859128 | The molecular basis of chemoradiosensitivity in rectal cancer:implications for personalized therapies |
| Q36906563 | The prognostic and predictive value of KRAS oncogene substitutions in lung adenocarcinoma |
| Q34365654 | The structural basis for cancer treatment decisions |
| Q92265928 | Transformation of normal cells by aberrant activation of YAP via cMyc with TEAD |
| Q42820759 | Treating KRAS-mutant NSCLC: latest evidence and clinical consequences |
| Q37031288 | Up-regulation of c-MYC and SIRT1 expression correlates with malignant transformation in the serrated route to colorectal cancer |
| Q34622865 | Worse prognosis of KRAS c.35 G > A mutant metastatic colorectal cancer (MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx) |
| Q28583902 | p75-Ras-GRF1 is a c-Jun/AP-1 target protein: its up regulation results in increased Ras activity and is necessary for c-Jun-induced nonadherent growth of Rat1a cells |
Search more.